Vivos Therapeutics Acquires Stake in SOD Sciences, Eyes Chronic Disease Detection

  • Vivos Therapeutics to acquire 11% stake in SOD Sciences and 50% interest in pseudohypoxia test for $12M in Series C Preferred Stock.
  • Transaction expected to close October 15, 2026, subject to customary conditions.
  • Potential collaboration with Cleveland Clinic Weston and marketing relationship with AHA.
  • Vivos aims to regain Nasdaq compliance through increased stockholders’ equity.
  • Revenue sharing model: 80% contribution margin on Vivos products, 50/50 on joint test sales.

Vivos Therapeutics is expanding its diagnostic capabilities beyond sleep apnea into chronic disease detection, a strategic shift that aligns with growing industry focus on early intervention. The $12M transaction, while dilutive, aims to bolster stockholders’ equity and regain Nasdaq compliance, setting the stage for potential profitability in early 2027. Success hinges on executing high-margin partnerships and validating the pseudohypoxia test’s clinical utility.

Regulatory Compliance
Whether Vivos can regain Nasdaq compliance through this transaction and subsequent capital raising.
Revenue Potential
The pace at which joint marketing agreements with Cleveland Clinic and AHA can drive new revenue streams.
Clinical Validation
How quickly the pseudohypoxia test can be clinically validated to support commercialization efforts.